Prognostic factors for multiple myeloma in the era of novel therapies
- 2 November 2018
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Hematology
- Vol. 11 (11) , 863-879
Abstract
Introduction: Multiple myeloma (MM) is characterized by notable inter-patient and intra-clonal heterogeneity that is gradually decoded over the last decade. Despite the deeper and better understanding of its biology and the development of novel therapeutic strategies that have prolonged overall survival, MM still retains a poor prognosis in patient subgroups with certain high-risk features.Areas covered: This article summarizes currently identified features that stratified patients in high-risk myeloma with impaired prognosis and discusses available therapeutic options that may partially overcome the impact of these adverse factors in patients' outcome. Numerous molecular and genetic assays such as detection by fluorescent in situ hybridization (FISH) of cytogenetic aberrations, gene expression profiling, minimal residual disease assessment by flow cytometry, or next-generation sequencing as well as novel imaging modalities such as magnetic resonance imaging (MRI) and positron emission tomography-computed tomography (PET-CT) have considerably increased available tools for recognizing in advance patients with unfavorable outcome. In parallel, many novel agents, particularly in combination treatments, have significantly improved the natural evolution of high-risk disease.Expert commentary: Moving forward to the same direction, a more accurate identification of patients with high-risk MM will allow a more individualized and intensive approach in their management directly after diagnosis.Keywords
This publication has 167 references indexed in Scilit:
- Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trialThe Lancet Oncology, 2011
- Relationship between elevated immunoglobulin free light chain and the presence of IgH translocations in multiple myelomaLeukemia, 2010
- Homozygous Deletion Mapping in Myeloma Samples Identifies Genes and an Expression Signature Relevant to Pathogenesis and OutcomeClinical Cancer Research, 2010
- International Myeloma Working Group molecular classification of multiple myeloma: spotlight reviewLeukemia, 2009
- F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myelomaBlood, 2009
- An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myelomaBlood, 2008
- Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple MyelomaNew England Journal of Medicine, 2008
- Circulating mutant DNA to assess tumor dynamicsNature Medicine, 2008
- Improved survival in multiple myeloma and the impact of novel therapiesBlood, 2008
- Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myelomaBlood, 2008